[Mixed invasive fungal infection due to Rhizomucor pusillus and Aspergillus niger in an immunocompetent patient]

Rev Iberoam Micol. 2015 Jan-Mar;32(1):46-50. doi: 10.1016/j.riam.2013.03.002. Epub 2013 Apr 11.
[Article in Spanish]

Abstract

Background: Mucormycosis infections are rare in immunocompetent patients, and very few cases of mucormycosis associated with aspergillosis in non-haematological patients have been reported.

Case report: A 17-year-old male, immunocompetent and without any previously known risk factors, was admitted to hospital due to a seizure episode 11 days after a motorcycle accident. He had a complicated clinical course as he had a mixed invasive fungal infection with pulmonary involvement due to Aspergillus niger and disseminated mucormycosis due to Rhizomucor pusillus (histopathological and microbiological diagnosis in several non-contiguous sites). He was treated with liposomal amphotericin B for 7 weeks (total cumulative dose >10 g) and required several surgical operations. The patient survived and was discharged from ICU after 5 months and multiple complications.

Conclusions: Treatment with liposomal amphotericin B and aggressive surgical management achieved the eradication of a mixed invasive fungal infection. However, we emphasise the need to maintain a higher level of clinical suspicion and to perform microbiological techniques for early diagnosis of invasive fungal infections in non-immunocompromised patients, in order to prevent spread of the disease and the poor prognosis associated with it.

Keywords: Anfotericina B liposomal; Aspergilosis pulmonar; Disseminated mucormycosis; Immunocompetent; Infección fúngica invasiva mixta; Inmunocompetente; Liposomal amphotericin B; Mixed invasive fungal infection; Mucormicosis diseminada; Pulmonary aspergillosis; Rhizomucor pusillus.

Publication types

  • Case Reports

MeSH terms

  • Accidents, Traffic
  • Adolescent
  • Akinetic Mutism / etiology
  • Amphotericin B / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Antifungal Agents / therapeutic use
  • Aspergillosis / complications*
  • Aspergillosis / drug therapy
  • Aspergillosis / microbiology
  • Aspergillus niger / isolation & purification*
  • Coinfection / drug therapy
  • Coinfection / microbiology
  • Combined Modality Therapy
  • Craniocerebral Trauma / complications*
  • Craniocerebral Trauma / surgery
  • Critical Care / methods
  • Gastrointestinal Diseases / etiology
  • Gastrointestinal Diseases / surgery
  • Humans
  • Immunocompetence*
  • Lung Diseases, Fungal / complications
  • Lung Diseases, Fungal / drug therapy
  • Lung Diseases, Fungal / microbiology
  • Lung Diseases, Fungal / surgery
  • Male
  • Mucormycosis / complications*
  • Mucormycosis / drug therapy
  • Mucormycosis / microbiology
  • Postoperative Complications / microbiology
  • Rhizomucor / isolation & purification*
  • Skull Fractures / etiology
  • Skull Fractures / surgery
  • Ulcer / etiology
  • Ulcer / surgery
  • Wound Infection / microbiology*

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • liposomal amphotericin B
  • Amphotericin B